• 5 min read
• Published on 9 January 2026
Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
View the full Basket:Radiopharma Revolution: Promise Meets Market Risk
Every so often, a corner of the market that was once the preserve of lab coats and PhDs suddenly becomes the talk of the town. This time, it’s radiopharmaceuticals. And if you’re wondering whether you should pay attention, let me tell you this, when a giant like Eli Lilly throws its weight, and a considerable amount of cash, behind a new listing, I tend to sit up and listen. The recent IPO of Aktis Oncology wasn't just a success, it was a flare in the sky for investors.
View the full Basket:Radiopharma Revolution: Promise Meets Market Risk
Let's be clear. Most biotech IPOs are a punt, a shot in the dark on a promising molecule. Aktis Oncology’s debut felt different. Not only did they raise a hefty $318 million, but they did it with Eli Lilly signing on as a major backer. To me, that’s not just an investment. It’s a strategic nod from one of the sharpest operators in the business. It signals a belief that this technology, which sounds like something from a science fiction novel, has a real commercial future. The ripple effect was immediate, with money and attention flowing back into a sector that had been quietly ticking away in the background.
View the full Basket:Radiopharma Revolution: Promise Meets Market Risk
So, what are we actually talking about? In essence, radiopharmaceuticals are molecular smart bombs. You take a radioactive particle, the warhead, and attach it to a targeting agent that is obsessed with finding one specific type of cancer cell. The result is a treatment that hunts down and irradiates tumours whilst, in theory, leaving healthy tissue alone. It’s an elegant, if slightly terrifying, concept. We already know it can work wonders. Just look at Novartis and their prostate cancer drug, Pluvicto, which pulled in over a billion dollars last year. That’s the kind of figure that turns a scientific curiosity into a serious investment thesis.
View the full Basket:Radiopharma Revolution: Promise Meets Market Risk
Now, before you rush off to remortgage the house, let's inject a healthy dose of cynicism. This is biotech, the investment world’s equivalent of a high-stakes poker game. For every success story like Pluvicto, there is a graveyard of failed clinical trials and burnt-out companies. The radiopharma space comes with its own unique set of headaches, too. Handling radioactive materials isn't like mixing chemicals in a beaker. It demands eye-wateringly expensive facilities, fiendishly complex supply chains, and safety protocols that would make a nuclear submarine commander nervous. The potential rewards are huge, but let’s not pretend the risks aren’t just as colossal.
View the full Basket:Radiopharma Revolution: Promise Meets Market Risk
The beauty of this sector is that it’s not just about one plucky start-up. You have established giants like Eli Lilly and Merck dipping their toes in, likely looking to pair these new smart bombs with their existing cancer treatments. Then you have the smaller, more focused players working on the next generation of therapies. It's a whole ecosystem. An investment here isn’t just a bet on a single drug, but on a fundamental shift in how we approach one of humanity’s worst diseases. The convergence of an ageing global population and the limitations of old-school chemotherapy creates a powerful tailwind. It's a fascinating, if perilous, field. For those with the stomach for it, grouping these companies together makes a certain kind of sense. The collection of stocks in the Radiopharma Revolution: Promise Meets Market Risk basket gives you a cross-section of this high-stakes world. This approach may help spread the risk, though nothing can eliminate it entirely in a sector this volatile.
View the full Basket:Radiopharma Revolution: Promise Meets Market Risk
View the full Basket:Radiopharma Revolution: Promise Meets Market Risk
View the full Basket:Radiopharma Revolution: Promise Meets Market Risk
View the full Basket:Radiopharma Revolution: Promise Meets Market Risk
View the full Basket:Radiopharma Revolution: Promise Meets Market Risk
View the full Basket:Radiopharma Revolution: Promise Meets Market Risk
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article
published-on
Read article